Earnings call transcript: Molina Healthcare Q2 2025 misses EPS forecast, stock drops

Molina Healthcare reported mixed Q2 2025 results, with adjusted earnings per share of $5.48 falling short of the $5.82 forecast, despite revenue of $11.43 billion surpassing expectations. The company's stock reacted sharply, declining 12.41% in after-hours trading, as a higher-than-anticipated consolidated Medical Cost Ratio (MCR) of 90.4% reflected significant increases in medical costs, particularly in behavioral health and pharmacy. Consequently, Molina lowered its full-year 2025 adjusted EPS guidance to 'no less than $19 per share' from an initial $24.50, though management emphasized ongoing cost control protocols and strong state advocacy to address these industry-wide cost pressures and maintain long-term growth targets.

Analysis

Molina Healthcare reported a challenging second quarter for 2025, characterized by a significant earnings miss and a sharp downward revision to its full-year guidance. The company's adjusted EPS of $5.48 fell 5.84% short of the $5.82 forecast, triggering a 12.41% decline in its stock during after-hours trading. This occurred despite a 4.48% revenue beat, with revenues reaching $11.43 billion. The core issue is an unprecedented surge in medical costs, pushing the consolidated Medical Cost Ratio (MCR) to 90.4%. Management detailed that these cost pressures are broad-based, affecting Medicaid (91.3% MCR), Medicare (90% MCR), and the Marketplace (85.4% MCR) segments, with specific drivers including behavioral health, high-cost pharmacy drugs, and increased inpatient/outpatient utilization. The Marketplace business, while only 10% of revenue, accounts for nearly half of the negative MCR variance, exacerbated by a market-wide 8% increase in risk pool acuity that has blunted the effectiveness of risk-adjustment mechanisms. In response, management cut full-year 2025 adjusted EPS guidance to a floor of '$19 per share,' a substantial reduction from the initial $24.50. However, the company is actively pursuing countermeasures, including aggressive rate advocacy with state partners for its Medicaid business and significant repricing for its 2026 Marketplace products to restore margins. Long-term premium revenue targets of $46 billion for 2026 and $52 billion for 2027 remain intact, supported by an unchanged embedded earnings estimate of $8.65 per share from new contracts and acquisitions.

Key Decisions for Investors

• Investors should recognize the significant near-term pressure on profitability, as evidenced by the severe 2025 EPS guidance cut to a $19 floor and the stock's sharp negative reaction, driven by systemic and 'unprecedented' medical cost inflation.
• The primary catalyst for a potential rebound hinges on management's ability to successfully re-negotiate Medicaid rates for 2026 and reprice its Marketplace products to offset the higher cost trends; the outcomes of these actions should be closely monitored.
• For value-oriented investors, the substantial stock price decline may present a contrarian opportunity, given that long-term revenue growth targets and an $8.65 per share embedded earnings figure remain, though this thesis depends on the cyclicality of cost trends and successful execution of margin recovery strategies.
• Pay close attention to legislative risks, including the potential for Marketplace subsidy expirations and the gradual implementation of new Medicaid rules post-2027, which could introduce further volatility to membership and risk pools.